![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » COBALIS' EU PATENT FOR PREHISTIN BECOMES EFFECTIVE
COBALIS' EU PATENT FOR PREHISTIN BECOMES EFFECTIVE
June 21, 2006
Cobalis Corp., a pharmaceutical development company focused on the treatment of allergy and other atopic conditions, announced today that its Patent No. 1128835, titled "Cyanocobalamin Treatment in Allergic Disease," has been published by the European Patent Office in the European Patent Bulletin 06/25. With its publication today, the patent is now in effect and protects the method of treatment underlying Cobalis' PreHistin anti-allergy medication.
Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=2761461)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct